GlobeNewswire by notified

Brains Bio Receives NSF’s First CBD Certification for EU GMP CBD API

Share

The independent, third-party certification confirms that the company’s facility and EU GMP CBD products have attained NSF Certified for Sport® certification

VANCOUVER, British Columbia, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp ("Brains Bio" or the "Company"), a global leader in EU GMP grade Cannabidiol (CBD) has received NSF GMP certification (NSF/ANSI 173, Section 8) for its EU GMP manufacturing facility in the UK. Cannabidiol produced from this facility is an NSF certified Dietary Ingredient (NSF/ANSI standard 173) and Raw Ingredient (Guideline 306), validating claims it has been tested for banned substances, heavy metals, microbials and pesticides.

"Brains Bio remains committed to providing quality, certified ingredients that ensure product integrity while meeting market demands. NSF certification reaffirms our commitment to supplying natural and sustainable cannabinoid ingredients in a rapidly growing marketplace,” said Ricky Brar, CEO and Chairperson of Brains Bio. "NSF certification allows us to supply CBD products tested for more than 280 athletically banned substances to our world-class roster of Olympians and athletes around the globe, giving them absolute assurance of purity."

This verification will allow the company to partner with leading global sports and nutrition brands such as Brain's deal with the UK’s largest vitamin company. This comes following the recent announcement from the Major League Baseball (MLB) allowing teams to work only with CBD brands which are NSF Certified for Sport®.

Through its wholly-owned subsidiary BSPG Laboratories, Brains has provided EU GMP CBD for clinical research around the globe for over seven years. With EU and UK-validated novel foods applications, the company now has 19 validated finished products in the UK and validation for its isolate across the EU. The company’s portfolio of proprietary formulations includes oils, sprays, topicals, gummies, capsules, water enhancers, and patches. its natural ingredients go through rigorous quality-control processes to ensure they meet the high-quality standards in the industry.

“We’re excited to announce that Brains Bio is the first company in the world to earn certification from NSF for a CBD ingredient,” said John Travis, Technical Manager for NSF Certified for Sport®. “NSF welcomes Brains Bio to the Certified for Sport® program. NSF is committed to protecting and improving human health worldwide. By meeting our rigorous Certified for Sport® requirements, Brains Bio is demonstrating its commitment to clean sport as well as quality, safety and good manufacturing processes.”

To earn NSF certification, Brains Bio completed a rigorous site inspection and ingredient testing process, verifying that good manufacturing practices are in place and its products have been tested for banned substances, pesticides, and heavy metals.

The certified plant-based EU GMP CBD products, manufacturing facility, and related marketing materials of Brains would bear the NSF Ingredient certification to show product manufacturers and brands that the ingredient quality has met rigorous standards. The above-mentioned list of NSF certifications can be found on NSF data base search domain (https://www.nsf.org/certified-products-systems).

Brains Bio’s market-leading position is further enhanced by its pharmaceutical regulatory package, which includes:

  • German DAC monograph compliant.
  • 36-Month stability data.
  • Over 350 commercial batches manufactured with resulting batch consistency and standardization data.
  • Approved IND filings with the US FDA.
  • Non-GMO, Kosher and Halal certified
  • Tested for banned substances by NSF, Informed Choice, and INRS (a WADA-certified lab)

Brains will also work with its partners and manufacturers, including the UK’s largest vitamin company, to supply EU GMP CBD products with NSF-certified ingredients while still meeting some of the highest quality standards, including ICHQ7, EU GMP, non-GMO, organic, and kosher, among others.

For media inquiries, please contact:
media@brainsbio.com

For investor relations, please contact:
ir@brainsbio.com

Follow Brains Bio on Social:
Twitter: @BrainsBio, LinkedIn: @BrainsBio, Instagram: @BrainsPure

ABOUT BRAINS BIOCEUTICAL CORP.
Brains Bioceutical is the leader in evidence-based Phyto-cannabinoid health solutions to enhance life and treatment options for all.

Brains Bio is a leading manufacturer of natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, Brains Bio is strategically positioned to take advantage of the complex regulatory environment, securing its first-mover and product quality advantage. Brains Bio is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market, resulting in a strong and unique value proposition.

By partnering with industry leaders in the pharmaceutical and nutraceutical industries, Brains Bio is positioned for hyper-growth by leveraging the existing brand equity, resources, and experience of its major partners.

About NSF

NSF is an independent, global organization that facilitates standards development to minimize adverse health effects and protect the environment. With operations in 180 countries, NSF tests and certifies products for the food, water, health sciences, and consumer goods industries. Founded in 1944, NSF is committed to protecting human health and safety worldwide. NSF is a Pan American Health Organization and a World Health Organization Collaborating Centre on Water Quality, Food Safety, and Medical Device Safety.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10

Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Landsbankinn hf.: Results of the 2024 AGM of Landsbankinn19.4.2024 20:48:08 CEST | Press release

The annual general meeting (AGM) of Landsbankinn, held on 19 April 2024, agreed to pay a dividend amounting to ISK 16,535 million to shareholders. The dividend is equivalent to 50% of 2023 profits. The dividend will be paid in two instalments, firstly on 24 April 2024 and secondly on 16 October 2024. As a result, total dividend paid by the Bank in 2013-2024 amounts to ISK 191.7 billion. At the AGM, held in Reykjastræti 6, Helga Björk Eiríksdóttir, Chairman of the Board of Directors, delivered the report from the Board for 2023. Lilja Björk Einarsdóttir, CEO, spoke of the Bank’s operation, strategy and activities in the past operating year. The annual financial statement for the past operating year was approved, as was the proposed Remuneration Policy and remuneration to Directors of the Board. The AGM elected the Auditor General (Ríkisendurskoðun) as auditor of Landsbankinn hf. for the 2024 operating year. The Auditor General, in accordance with an authorisation to outsource tasks, and

SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.19.4.2024 19:20:57 CEST | Press release

Reference is made to the announcement dated 31 January 2024, regarding Styrkás hf., a company 69.64% owned by SKEL fjárfestingafélag hf., signing a purchase agreement to acquire 100% of the shares in six subsidiaries of Máttarstólpi ehf. The purchase agreement was subject to the approval of the Competition Authority. The transaction was finalized today with payment of purchase price and delivering of shares in the following companies: - Stólpi Gámar ehf., id. 460121-1590, Klettagörðum 5, 104 Reykjavík: - Stólpi Smiðja ehf., id. 460121-1750, Klettagörðum 5, 104 Reykjavík; - Klettskjól ehf., id. 460121-0510, Klettagörðum 5, 104 Reykjavík; - Stólpi ehf., 460121-0430, Klettagörðum 5, 104 Reykjavík; - Tjónaþjónustan ehf., id. 460121-1670, Klettagörðum 5, 104 Reykjavík; - Alkul ehf., id. 491020-0830, Haukdælabraut 48, 113 Reykjavík. collectively referred to as "the sold companies". These companies will continue to be operated on a consolidated basis. The Enterprise value of the sold companie

HiddenA line styled icon from Orion Icon Library.Eye